GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group’s board. The decision to go hostile with the $13-a-share cash tender offer sets up GSK for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough.

View the original article here: GSK goes hostile with $2.6 billion Human Genome offer